This Article Full Text Full Text (PDF) Supplementary Data Supplementary Data Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by French, P. J. Articles by Sillevis Smitt, P. A. Search for Related Content PubMed PubMed Citation Articles by French, P. J. Articles by Sillevis Smitt, P. A.

Gene Expression Profiles Associated with Treatment Response in Oligodendrogliomas

Departments of ¹ Neurology, ² Bioinformatics, ³ Pathology, ⁴ Medical Oncology, and ⁵ Cell Biology and Genetics, Cancer Genomics Center, Erasmus Medical Center, Rotterdam, the Netherlands

Requests for reprints: Pim J. French, Department Neurology, Josephine Nefkens Institute, Erasmus Medical Center, Room Be462a, P.O. Box 1738, 3000 DR Rotterdam, the Netherlands. Phone: 31-10-408-8333; Fax: 31-10-408-8365; E-mail: p.french{at}erasmusmc.nl.

Oligodendrogliomas are a specific subtype of brain tumor of which the majority responds favorably to chemotherapy. In this study, we made use of expression profiling to identify chemosensitive oligodendroglial tumors. Correlation of expression profiles to loss of heterozygosity on 1p and 19q, common chromosomal aberrations associated with response to treatment, identified 376, 64, and 60 differentially expressed probe sets associated with loss of 1p, 19q or 1p, and 19q, respectively. Correlation of expression profiles to the tumors' response to treatment identified 16 differentially expressed probe sets. Because transcripts associated with chemotherapeutic response were identified independent of common chromosomal aberrations, expression profiling may be used as an alternative approach to the tumors' 1p status to identify chemosensitive oligodendroglial tumors. Finally, we correlated expression profiles to survival of the patient after diagnosis and identified 103 differentially expressed probe sets. The observation that many genes are differentially expressed between long and short survivors indicates that the genetic background of the tumor is an important factor in determining the prognosis of the patient. Furthermore, these transcripts can help identify patient subgroups that are associated with favorable prognosis. Our study is the first to correlate gene expression with chromosomal aberrations and clinical performance (response to treatment and survival) in oligodendrogliomas. The differentially expressed transcripts can help identify patient subgroups with good prognosis and those that will benefit from chemotherapeutic treatments. (Cancer Res 2005; 65(24): 11335-44)

This article has been cited by other articles:

				P. J. French, J. Peeters, S. Horsman, E. Duijm, I. Siccama, M. J. van den Bent, T. M. Luider, J. M. Kros, P. van der Spek, and P. A. Sillevis Smitt Identification of Differentially Regulated Splice Variants and Novel Exons in Glial Brain Tumors Using Exon Expression Arrays Cancer Res., June 15, 2007; 67(12): 5635 - 5642. [Abstract] [Full Text] [PDF]